Drug intelligence / Profile preview

Jimu Granules

Development stage: Unknown
Lead developer: Beijing White Flower Loropetalum Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

Jimu Granules is a Traditional Chinese Medicine (TCM) candidate developed by Beijing White Flower Loropetalum Biotechnology Co., Ltd. for the treatment of chronic non-atrophic gastritis. The drug is derived from the plant *Loropetalum chinense* (White Flower Loropetalum) and is specifically indicated for patients presenting with the "stomach heat and dampness" syndrome. It is thought to work by reducing gastric mucosal inflammation and providing cytoprotection. Jimu Granules has advanced to Phase 3 clinical trials in China, where its efficacy in relieving symptoms like epigastric pain and bloating is being compared against standard care or placebo.

Brand names: Jimu Granules
Other names: Jimu Keli棘木颗粒

Beyond the preview

Go deeper on Jimu Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jimu Granules.

Explore the full profile